Zai Lab Limited (ADR)
General ticker "ZLAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B (TTM average)
Zai Lab Limited (ADR) follows the US Stock Market performance with the rate: 1.2%.
Estimated limits based on current volatility of 2.1%: low 25.82$, high 26.90$
Factors to consider:
- Total employees count: 1869 (-14.1%) as of 2024
- Top business risk factors: Inability to achieve profitability, Lack of market acceptance, Regulatory and compliance, Clinical trial failure, Market competition
- Current price 24.9% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.67$, 21.62$]
- 2026-12-31 to 2027-12-31 estimated range: [5.85$, 16.46$]
Financial Metrics affecting the ZLAB estimates:
- Negative: with PPE of -11.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.70 <= 0.28
- Positive: Investing cash flow per share per price, % of 15.72 > -0.64
- Positive: Interest expense per share per price, % of 0.27 <= 0.75
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ZLAB quotes
Long-term ZLAB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $266.72MM | $398.99MM | $460.16MM |
| Operating Expenses | $633.29MM | $681.11MM | $683.73MM |
| Operating Income | $-366.57MM | $-282.12MM | $-223.57MM |
| Non-Operating Income | $31.95MM | $25.01MM | $45.11MM |
| Interest Expense | $0.00MM | $2.25MM | $5.21MM |
| R&D Expense | $265.87MM | $234.50MM | $220.90MM |
| Income(Loss) | $-334.62MM | $-257.10MM | $-178.46MM |
| Taxes | $0.00MM | $0.00MM | $-2.93MM |
| Net Income(Loss)* | $-334.62MM | $-257.10MM | $-175.54MM |
| Stockholders Equity | $796.12MM | $840.90MM | $715.50MM |
| Inventory | $44.83MM | $39.88MM | $74.75MM |
| Assets | $1,036.30MM | $1,185.75MM | $1,172.38MM |
| Operating Cash Flow | $-198.18MM | $-214.87MM | $-150.79MM |
| Capital expenditure | $8.49MM | $61.52MM | $13.42MM |
| Investing Cash Flow | $-10.78MM | $-375.19MM | $307.87MM |
| Financing Cash Flow | $-6.43MM | $349.89MM | $72.35MM |
| Earnings Per Share** | $-34.63 | $-2.60 | $-1.60 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.